Alexza to Webcast Investor and Analyst Day Presentations

MOUNTAIN VIEW, Calif., April 22 /PRNewswire-FirstCall/ -- Alexza
Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it will host a live
audio webcast of presentations given at the Company's Investor and Analyst Day
on Tuesday, April 29th, 2008. Leading medical experts will discuss the Phase
1 and Phase 2 results of the Company's clinical trials, provide an overview of
the Phase 3 trial design for AZ-004 (Staccato(R) loxapine), and discuss the
role that AZ-004 may play in treating acute agitation in schizophrenic or
bipolar disorder patients. Alexza senior management will also provide an
overview of Alexza's other clinical stage product candidates.
What: Presentations (Audio & Slides)

Who: Dr. Michael Allen - University of Colorado Health Sciences
Center
Associate Professor of Psychiatry
Director, Emergency and Consultation Psychiatry
Co-Director, Mood Disorders Program
Past President and Trustee, American Association for
Emergency Psychiatry

Dr. Carol Tamminga -- University of Texas Southwestern
Medical Center
Professor of Psychiatry
Vice Chair for Clinical Research
Chief of Translational Neuroscience Research in
Schizophrenia
Communities Foundation of Texas Chair in Brain Science

When: Tuesday, April 29th, 2008 at 12:15-3:00 p.m. EDT

Where: here
eventDetails&c=196151&eventID=1831771
or
here

How: Live over the Internet -- Simply log on to the Web at the
address above and register for the event (approximately 10
minutes beforehand)

If you are unable to participate during the live webcast, the call will be
archived on Alexza's website at www.alexza.com.
About Alexza Pharmaceuticals
Alexza Pharmaceuticals is an emerging specialty pharmaceutical company
focused on the development and commercialization of novel, proprietary
products for the treatment of acute and intermittent conditions. The
Company's technology, the Staccato system, vaporizes unformulated drug to form
a condensation aerosol that allows rapid systemic drug delivery through deep
lung inhalation. The drug is quickly absorbed through the lungs into the
bloodstream, providing speed of therapeutic onset that is comparable to
intravenous administration, but with greater ease, patient comfort and
convenience.
Alexza has six product candidates in clinical development. Alexza's lead
program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in
schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001
(Staccato prochlorperazine) for the acute treatment of migraine headaches has
completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment
of migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatment
of panic attacks associated with panic disorder are in Phase 2 testing.
Product candidates in Phase 1 testing include AZ-003 (Staccato fentanyl) for
the treatment of breakthrough pain, which is partnered with Endo
Pharmaceuticals in North America, and AZ-007 (Staccato zaleplon) for the
treatment of insomnia. More information, including this and past press
releases from Alexza is available online at www.alexza.com.
Safe Harbor Statement
The anticipated webcast and presentations will contain forward-looking
statements that involve significant risks and uncertainties. Any statement
describing the Company's expectations or beliefs is a forward-looking
statement, as defined in the Private Securities Litigation Reform Act of 1995,
and should be considered an at-risk statement. Such statements are subject to
certain risks and uncertainties, particularly those inherent in the process of
developing and commercializing drugs. The Company's forward-looking
statements also involve assumptions that, if they prove incorrect, would cause
its results to differ materially from those expressed or implied by such
forward-looking statements. These and other risks concerning Alexza's
business are described in additional detail in the Company's Annual Report on
Form 10-K for the year ended December 31, 2007, and the Company's other
Periodic and Current Reports filed with the Securities and Exchange
Commission, including the risks under the headings. Forward-looking
statements contained in the webcast and presentations are made as of their
date of presentation, and the Company undertakes no obligation to publicly
update any forward-looking statement, whether as a result of new information,
future events or otherwise.
SOURCE Alexza Pharmaceuticals, Inc.

Thomas B. King, President & CEO of Alexza Pharmaceuticals, +1-650-944-7634,
tking@alexza.com